Opus Genetics Reports 29.2% Revenue Growth in FY 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Should l Buy IRD?
Source: seekingalpha
- Financial Performance: Opus Genetics reported a GAAP EPS of -$0.80 for FY 2025, yet achieved revenue of $14.2 million, reflecting a 29.2% year-over-year growth, indicating strong growth potential in collaborative projects.
- Collaboration Revenue: The company generated $14.2 million in licensing and collaboration revenue from Viatris, Inc. in FY 2025, up from $11.0 million in FY 2024, highlighting sustained demand for its R&D services.
- Cash Position: As of December 31, 2025, Opus Genetics had cash and cash equivalents of $45.1 million and raised approximately $25.0 million through a private placement, enhancing its financial flexibility.
- Operational Funding Outlook: The company believes its total cash resources of $70.1 million will fund operations into the first half of 2028, excluding any potential proceeds from callable warrants or future milestone payments, demonstrating long-term operational sustainability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRD
Wall Street analysts forecast IRD stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.260
Low
6.00
Averages
8.00
High
9.00
Current: 5.260
Low
6.00
Averages
8.00
High
9.00
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Opus Genetics Reports Vision Restoration Data in Pediatric Patients
- Clinical Data Breakthrough: Opus Genetics presented six-month clinical data at the ARVO Annual Meeting indicating that LCA5 gene therapy successfully restores cone-mediated vision in pediatric patients, with sensitivity improvements exceeding 30-fold, highlighting the treatment's efficacy and potential market demand.
- Vision Function Improvement: Following a single subretinal injection, patients demonstrated early and durable improvements in functional vision tests, suggesting that even in severe early-onset diseases, there remains an opportunity for vision restoration, potentially laying the groundwork for future treatment options.
- Multiple Research Advancements: Preliminary results indicate that BEST1 gene therapy also achieved improvements in visual acuity in adult patients with no significant adverse reactions, supporting Opus Genetics' broader rollout of its gene therapy products across a larger population.
- Technological Innovation and Scalability: The company's developed cell-based expression and functional potency assays demonstrated consistent efficacy, supporting its capabilities in regulatory readiness and scalable production, further enhancing its competitive edge in the gene therapy sector.
See More
Opus Genetics Receives FDA RDEP Designation for LCA5 Gene Therapy
- FDA RDEP Designation: Opus Genetics announced that its OPGx-LCA5 gene therapy program has received the Rare Disease Evidence Principle (RDEP) designation from the FDA, marking a significant advancement in the treatment of LCA5 retinal disease and expected to expedite clinical development.
- Disease Context: LCA5 is a rare inherited retinal disease caused by biallelic mutations in the LCA5 gene, leading to severe visual impairment in childhood, with no FDA-approved therapies currently available, highlighting the market potential for this treatment.
- Therapeutic Mechanism: The OPGx-LCA5 gene therapy delivers a functional LCA5 gene to the outer retina using an adeno-associated viral vector and has previously received FDA designations as a rare pediatric disease, orphan drug, and regenerative medicine advanced therapy (RMAT), indicating its innovative nature in the treatment landscape.
- Clinical Trial Progress: The company is currently evaluating OPGx-LCA5 in an ongoing Phase 1/2 trial and plans to align with the FDA on the pivotal Phase 3 program, which is expected to provide new treatment options for patients and drive future growth for the company.
See More
Opus Genetics' OPGx-LCA5 Accepted into FDA's Rare Disease Program
- FDA Program Participation: Opus Genetics' OPGx-LCA5 gene therapy has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program, marking a significant regulatory support milestone that is expected to expedite clinical trial design and approval processes for treatments targeting LCA5.
- Clinical Trial Progress: Currently undergoing a Phase 1/2 clinical trial at the University of Pennsylvania, OPGx-LCA5 has shown promising results with pediatric participants demonstrating significant vision improvements and good tolerability, with no serious adverse events reported, indicating the therapy's potential efficacy.
- Strategic Importance: By obtaining RDEP eligibility, Opus Genetics can engage in early and ongoing collaboration with the FDA, which not only aids in optimizing its pivotal Phase 3 program but also potentially provides faster treatment options for patients, addressing the urgent market demand for effective therapies.
- Multiple Designations: OPGx-LCA5 has also received FDA designations as a Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT), further enhancing its competitive position in the market and paving the way for future commercialization.
See More
Opus Genetics to Present Three Studies at ASCRS Annual Meeting
- Research Presentation: Opus Genetics will showcase three significant studies at the 2026 ASCRS Annual Meeting, including full results from VEGA-3, which evaluates the efficacy of 0.75% phentolamine ophthalmic solution for presbyopia, highlighting the company's strength in ophthalmology research.
- Clinical Trial Updates: The encore presentation of LYNX-2 will explore the impact of phentolamine ophthalmic solution on visual disturbances in low-light conditions, indicating the product's potential to improve patient visual quality and possibly drive future market applications.
- Educational Symposium Support: Opus's partner Viatris has provided independent funding for an educational symposium titled “Presbyopia Re-Envisioned: A New Era of Pharmacological Vision Correction,” aimed at fostering peer exchange and supporting clinicians in managing presbyopia, thereby enhancing the company's influence in the professional community.
- Market Demand Insight: Presbyopia affects approximately 128 million people in the U.S., with projections indicating that 2.1 billion people globally will be affected by 2030; Opus's research and product development align perfectly with this vast market demand, presenting significant commercial potential.
See More
Opus Genetics Presents New Research at ASCRS Meeting
- Research Presentation: Opus Genetics will present three significant studies at the 2026 ASCRS Annual Meeting, including full results from VEGA-3, evaluating the efficacy of 0.75% phentolamine ophthalmic solution for presbyopia, highlighting its potential in vision restoration.
- Clinical Trial Updates: Results from the LYNX-2 study will be showcased again, focusing on the improvement of visual disturbances in low-light conditions for post-refractive surgery patients using 0.75% phentolamine, underscoring its clinical relevance.
- Collaboration and Funding: The global licensing agreement with Viatris supports the development of 0.75% phentolamine, with Viatris providing independent funding for an educational symposium aimed at enhancing peer-to-peer exchange among clinicians.
- Market Demand Insight: Presbyopia affects approximately 128 million people in the U.S., with projections indicating 2.1 billion globally by 2030, positioning Opus's research to address this growing market need with effective treatment solutions.
See More
Opus Genetics Secures $155 Million Financing Agreement
- Financing Agreement: Opus Genetics has entered into a financing agreement with Oberland Capital Management, providing up to $155 million in non-dilutive funding, including an initial $35 million tranche and a $5 million equity investment, aimed at supporting the development and commercialization of its inherited retinal disease pipeline.
- Clear Funding Purpose: The funding will be utilized for development, manufacturing, and potential commercialization, particularly for pivotal studies of OPGx-LCA5 and OPGx-BEST1, while also advancing earlier-stage candidates into clinical trials, enhancing the company's competitive edge in gene therapy.
- Cash Flow Extension: With a current cash position of approximately $100 million, the financing is expected to extend Opus's cash runway into 2029, ensuring the company can continue to advance key programs and meet future funding needs.
- Positive Market Reaction: Following the financing announcement, Opus Genetics saw its stock price rise by 1.12% in pre-market trading to $4.60 per share, reflecting market confidence in the company's future growth and positive investor sentiment.
See More
Opus Genetics Reports Vision Restoration Data in Pediatric Patients
- Clinical Data Breakthrough: Opus Genetics presented six-month clinical data at the ARVO Annual Meeting indicating that LCA5 gene therapy successfully restores cone-mediated vision in pediatric patients, with sensitivity improvements exceeding 30-fold, highlighting the treatment's efficacy and potential market demand.
- Vision Function Improvement: Following a single subretinal injection, patients demonstrated early and durable improvements in functional vision tests, suggesting that even in severe early-onset diseases, there remains an opportunity for vision restoration, potentially laying the groundwork for future treatment options.
- Multiple Research Advancements: Preliminary results indicate that BEST1 gene therapy also achieved improvements in visual acuity in adult patients with no significant adverse reactions, supporting Opus Genetics' broader rollout of its gene therapy products across a larger population.
- Technological Innovation and Scalability: The company's developed cell-based expression and functional potency assays demonstrated consistent efficacy, supporting its capabilities in regulatory readiness and scalable production, further enhancing its competitive edge in the gene therapy sector.
See More
Opus Genetics Receives FDA RDEP Designation for LCA5 Gene Therapy
- FDA RDEP Designation: Opus Genetics announced that its OPGx-LCA5 gene therapy program has received the Rare Disease Evidence Principle (RDEP) designation from the FDA, marking a significant advancement in the treatment of LCA5 retinal disease and expected to expedite clinical development.
- Disease Context: LCA5 is a rare inherited retinal disease caused by biallelic mutations in the LCA5 gene, leading to severe visual impairment in childhood, with no FDA-approved therapies currently available, highlighting the market potential for this treatment.
- Therapeutic Mechanism: The OPGx-LCA5 gene therapy delivers a functional LCA5 gene to the outer retina using an adeno-associated viral vector and has previously received FDA designations as a rare pediatric disease, orphan drug, and regenerative medicine advanced therapy (RMAT), indicating its innovative nature in the treatment landscape.
- Clinical Trial Progress: The company is currently evaluating OPGx-LCA5 in an ongoing Phase 1/2 trial and plans to align with the FDA on the pivotal Phase 3 program, which is expected to provide new treatment options for patients and drive future growth for the company.
See More
Opus Genetics' OPGx-LCA5 Accepted into FDA's Rare Disease Program
- FDA Program Participation: Opus Genetics' OPGx-LCA5 gene therapy has been accepted into the FDA's Rare Disease Evidence Principles (RDEP) program, marking a significant regulatory support milestone that is expected to expedite clinical trial design and approval processes for treatments targeting LCA5.
- Clinical Trial Progress: Currently undergoing a Phase 1/2 clinical trial at the University of Pennsylvania, OPGx-LCA5 has shown promising results with pediatric participants demonstrating significant vision improvements and good tolerability, with no serious adverse events reported, indicating the therapy's potential efficacy.
- Strategic Importance: By obtaining RDEP eligibility, Opus Genetics can engage in early and ongoing collaboration with the FDA, which not only aids in optimizing its pivotal Phase 3 program but also potentially provides faster treatment options for patients, addressing the urgent market demand for effective therapies.
- Multiple Designations: OPGx-LCA5 has also received FDA designations as a Rare Pediatric Disease, Orphan Drug, and Regenerative Medicine Advanced Therapy (RMAT), further enhancing its competitive position in the market and paving the way for future commercialization.
See More
Opus Genetics to Present Three Studies at ASCRS Annual Meeting
- Research Presentation: Opus Genetics will showcase three significant studies at the 2026 ASCRS Annual Meeting, including full results from VEGA-3, which evaluates the efficacy of 0.75% phentolamine ophthalmic solution for presbyopia, highlighting the company's strength in ophthalmology research.
- Clinical Trial Updates: The encore presentation of LYNX-2 will explore the impact of phentolamine ophthalmic solution on visual disturbances in low-light conditions, indicating the product's potential to improve patient visual quality and possibly drive future market applications.
- Educational Symposium Support: Opus's partner Viatris has provided independent funding for an educational symposium titled “Presbyopia Re-Envisioned: A New Era of Pharmacological Vision Correction,” aimed at fostering peer exchange and supporting clinicians in managing presbyopia, thereby enhancing the company's influence in the professional community.
- Market Demand Insight: Presbyopia affects approximately 128 million people in the U.S., with projections indicating that 2.1 billion people globally will be affected by 2030; Opus's research and product development align perfectly with this vast market demand, presenting significant commercial potential.
See More
Opus Genetics Presents New Research at ASCRS Meeting
- Research Presentation: Opus Genetics will present three significant studies at the 2026 ASCRS Annual Meeting, including full results from VEGA-3, evaluating the efficacy of 0.75% phentolamine ophthalmic solution for presbyopia, highlighting its potential in vision restoration.
- Clinical Trial Updates: Results from the LYNX-2 study will be showcased again, focusing on the improvement of visual disturbances in low-light conditions for post-refractive surgery patients using 0.75% phentolamine, underscoring its clinical relevance.
- Collaboration and Funding: The global licensing agreement with Viatris supports the development of 0.75% phentolamine, with Viatris providing independent funding for an educational symposium aimed at enhancing peer-to-peer exchange among clinicians.
- Market Demand Insight: Presbyopia affects approximately 128 million people in the U.S., with projections indicating 2.1 billion globally by 2030, positioning Opus's research to address this growing market need with effective treatment solutions.
See More
Opus Genetics Secures $155 Million Financing Agreement
- Financing Agreement: Opus Genetics has entered into a financing agreement with Oberland Capital Management, providing up to $155 million in non-dilutive funding, including an initial $35 million tranche and a $5 million equity investment, aimed at supporting the development and commercialization of its inherited retinal disease pipeline.
- Clear Funding Purpose: The funding will be utilized for development, manufacturing, and potential commercialization, particularly for pivotal studies of OPGx-LCA5 and OPGx-BEST1, while also advancing earlier-stage candidates into clinical trials, enhancing the company's competitive edge in gene therapy.
- Cash Flow Extension: With a current cash position of approximately $100 million, the financing is expected to extend Opus's cash runway into 2029, ensuring the company can continue to advance key programs and meet future funding needs.
- Positive Market Reaction: Following the financing announcement, Opus Genetics saw its stock price rise by 1.12% in pre-market trading to $4.60 per share, reflecting market confidence in the company's future growth and positive investor sentiment.
See More
